반려동물 귀감염증 치료 시장 규모, 점유율, 동향 분석 리포트 : 질환 유형별, 제품 유형별, 투여 방법별, 동물 유형별, 판매채널별, 지역별, 부문 예측(2025-2030년)

Companion Animal Ear Infection Treatment Market Growth & Trends:

The global companion animal ear infection treatment market size is expected to reach USD 1.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.11% from 2025 to 2030. The increasing prevalence of ear infections in companion animals is one of the factors responsible for the market growth. An ear infection is a second-most common condition in canines. Otitis Externa is a common disorder and one of the top reasons for increase dvet visits.

The COVID-19 pandemic acted as a catalyst for rapid business and economic changes. Moreover, popular trends, such as "bring your pet to work", are also supporting the market growth. Companies operating in this market are widely accepting different approaches to treat otitis in companion animals. For instance, in April 2020, VirbacintroducedEasotic, a prescription medicine specified for the topical treatment of otitis externa in canines.

The rising number of pet owners and awareness about animal health and hygiene will boost the market growth. For instance, as stated by the American Pet Products Association's National Pet Owners Survey 2019-2020, 63.4 million U.S. households own dogs. Thus, increasing pet ownership along with growing research & development activities in animal health accelerates the market growth. For example, Dechra Pharmaceuticals spent USD 40.31 million (£28.4 million) on R&D in 2020, while USD 35.62 million (£28.4 million) in 2019. Moreover, the humanization of pets further contributes to market growth.

Companion Animal Ear Infection Treatment Market Report Highlights:

• The anti-bacterial product segment accounted for the largest revenue share in 2024 and will retain the leading position throughout the forecast period
• This growth can be credited to the rising incidence of ear diseases in pets associated with the bacterial infection
• The topical segment is anticipated to have significant growth owing to the availability of a wide range of products and high demand for topical treatments
• The cats animal type segment is estimated to register the fastest CAGR over the forecast period owing to increased concerns regarding the health and hygiene of cats
• The otitis externa disease segment is projected to register considerable growth as it is one of the most common and recurrent problems

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mode of Administration
  • 1.2.3. Animal Type
  • 1.2.4. Disease Type
  • 1.2.5. Sales Channel
  • 1.2.6. Regional Scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Mode of Administration
  • 2.2.3. Animal Type
  • 2.2.4. Disease Type
  • 2.2.5. Sales Channel
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Companion Animal Ear Infection Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence Of Otitis Externa
    • 3.2.1.2. Growing Pet Population And Companion Animal Ownership
    • 3.2.1.3. Rising Penetration Of Pet Insurance
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rise In The Number Of Counterfeit Drugs
    • 3.2.2.2. Lack Of Sufficient Veterinarians
• 3.3. Companion Animal Ear Infection Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social Landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental Landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Companion Animal Ear Infection Treatment Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Companion Animal Ear Infection Treatment Market: Product Movement Analysis
• 4.3. Companion Animal Ear Infection Treatment Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Antibacterial
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.5.2. Aminoglycosides
    • 4.5.2.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.5.3. Fluoroquinolones
    • 4.5.3.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.5.4. Others Antibacterial Products
    • 4.5.4.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Anti-fungal
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.7. Corticosteroids
  • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.8. Other Products
  • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Companion Animal Ear Infection Treatment Market: Mode of Administration Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Companion Animal Ear Infection Treatment Market: Mode of Administration Movement Analysis
• 5.3. Companion Animal Ear Infection Treatment Market by Mode of Administration Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Topical
  • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. Oral
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Otic
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Companion Animal Ear Infection Treatment Market: Animal Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Companion Animal Ear Infection Treatment Market: Animal Type Movement Analysis
• 6.3. Companion Animal Ear Infection Treatment Market by Animal Type Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Dogs
  • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6. Cats
  • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Companion Animal Ear Infection Treatment Market: Disease Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Companion Animal Ear Infection Treatment Market: Disease Type Movement Analysis
• 7.3. Companion Animal Ear Infection Treatment Market by Disease Type Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Otitis Externa
  • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6. Otitis Media
  • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7. Otitis Interna
  • 7.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Companion Animal Ear Infection Treatment Market: Sales Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Companion Animal Ear Infection Treatment Market: Sales Channel Movement Analysis
• 8.3. Companion Animal Ear Infection Treatment Market by Sales Channel Outlook (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Hospital/ Clinic Pharmacy
  • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6. Retail Pharmacies
  • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7. E-commerce
  • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Companion Animal Ear Infection Treatment Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts for 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. Rest of Europe
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Rest of Europe market estimates and forecasts for 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts for 2018 to 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Rest of Asia-Pacific
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Rest of Asia-Pacific market estimates and forecasts for 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Rest of LA
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Rest of LA market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts for 2018 to 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
  • 9.7.3. Rest of MEA
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Rest of MEA market estimates and forecasts for 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Recent Developments & Impact Analysis by Key Market Participants
• 10.3. Company Market Share Analysis, 2024
• 10.4. Company Overview
  • 10.4.1. Zoetis
    • 10.4.1.1. Company Overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Elanco
    • 10.4.2.1. Company Overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Dechra Pharmaceuticals Plc.
    • 10.4.3.1. Company Overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Merck & Co
    • 10.4.4.1. Company Overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Boehringer Ingelheim
    • 10.4.5.1. Company Overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. OurPetsLife
    • 10.4.6.1. Company Overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Vetoquinol
    • 10.4.7.1. Company Overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Virbac
    • 10.4.8.1. Company Overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Ceva
    • 10.4.9.1. Company Overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Vedco Inc. (Covetrus)
    • 10.4.10.1. Company Overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Penn Veterinary Supply
    • 10.4.11.1. Company Overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product Benchmarking
    • 10.4.11.4. Strategic initiatives